• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[用超高剂量链激酶对深部静脉血栓进行纤溶治疗]

[Fibrinolytic treatment of deep venous thromboses with streptokinase at an ultrahigh dosage].

作者信息

Theiss W, Baumann G, Klein G

出版信息

Dtsch Med Wochenschr. 1987 Apr 24;112(17):668-74. doi: 10.1055/s-2008-1068118.

DOI:10.1055/s-2008-1068118
PMID:3569060
Abstract

Twenty-one patients with deep vein thrombosis were treated for six hours per day in accordance with an "ultrahigh" dose scheme with 1,500,000 units/hour streptokinase. A maximum of two such cycles were administered in the first ten patients, and the subsequent patients received up to five cycles as required. In terms of clinical chemical parameters, a pronounced lowering of fibrinogen with corresponding elevation of fibrin(ogen) cleavage products regularly occurred during the first cycle. There were great differences in the individual times for which these alterations persisted (12-72 hours). The alterations during the subsequent cycles were very much less, probably because of the pronounced lowering of the plasminogen concentration. The clinical tolerance (including hemorrhagic complications) was roughly comparable with that of a streptokinase treatment with conventional doses. Phlebographic checking of the result of treatment showed that the ultrahigh dosed intermittent dosage scheme is a highly effective treatment procedure with which the duration of treatment can be appreciably shortened compared to conventional dosage schemata: in four cases, a full recanalization could already be attained after a single cycle.

摘要

21例深静脉血栓形成患者按照每小时150万单位链激酶的“超高”剂量方案每天治疗6小时。前10例患者最多进行2个这样的疗程,随后的患者根据需要接受多达5个疗程。就临床化学参数而言,在第一个疗程中,纤维蛋白原明显降低,同时纤维蛋白(原)降解产物相应升高。这些改变持续的个体时间差异很大(12 - 72小时)。后续疗程中的改变要小得多,可能是因为纤溶酶原浓度明显降低。临床耐受性(包括出血并发症)与传统剂量链激酶治疗大致相当。对治疗结果进行静脉造影检查表明,超高剂量间歇给药方案是一种高效的治疗方法,与传统给药方案相比,可显著缩短治疗时间:4例患者在单个疗程后即可实现完全再通。

相似文献

1
[Fibrinolytic treatment of deep venous thromboses with streptokinase at an ultrahigh dosage].[用超高剂量链激酶对深部静脉血栓进行纤溶治疗]
Dtsch Med Wochenschr. 1987 Apr 24;112(17):668-74. doi: 10.1055/s-2008-1068118.
2
[Fibrinolytic therapy in deep venous thrombosis of the upper and lower extremity].[纤维蛋白溶解疗法治疗上肢和下肢深静脉血栓形成]
Fortschr Med. 1977 Apr 7;95(13):858-66.
3
[Ultra-high dose thrombolytic therapy with streptokinase in peripheral venous thrombosis].[链激酶超大量溶栓疗法治疗外周静脉血栓形成]
Med Klin (Munich). 1989 Apr 15;84(4):183-7, 226.
4
Fibrinolytic therapy of deep vein thrombosis with continuous intravenous infusion of a recombinant tissue plasminogen activator.采用重组组织型纤溶酶原激活剂持续静脉输注对深静脉血栓形成进行溶栓治疗。
Semin Thromb Hemost. 1991 Jan;17(1):48-54. doi: 10.1055/s-2007-1002589.
5
Controlled multicenter pilot study of urokinase- heparin and streptokinase in deep vein thrombosis.
Thromb Haemost. 1983 Oct 31;50(3):660-3.
6
Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.用尿激酶和链激酶治疗深静脉血栓形成期间的全身纤维蛋白溶解活性和抑制剂水平。
Thromb Haemost. 1983 Oct 31;50(3):664-8.
7
[Report of experiences with fibrinolytic therapy of deep venous thrombosis of the legs].[腿部深静脉血栓形成的纤维蛋白溶解疗法经验报告]
Anaesthesiol Reanim. 1990;15(2):81-5.
8
[Continuous intravenous infusion versus intermittent administration of streptokinase in patients with deep venous thrombosis of the lower extremity].[下肢深静脉血栓形成患者中链激酶持续静脉输注与间歇给药的比较]
Pol Tyg Lek. 1991;46(37-39):704-7.
9
[Thrombolytic treatment of venous thrombi with combined use of streptokinase and human plasminogen (author's transl)].链激酶与人体纤溶酶原联合应用治疗静脉血栓(作者译)
Dtsch Med Wochenschr. 1981 May 8;106(19):610-4. doi: 10.1055/s-2008-1070364.
10
[Deep venous thrombosis: streptokinase treatment with adaptation of the maintenance dosage].[深部静脉血栓形成:链激酶治疗及维持剂量调整]
Med Klin. 1980 Aug 1;75(16):580-6.

引用本文的文献

1
[Fibrinolytic therapy of deep vein thrombosis].
Med Klin (Munich). 1999 Mar 15;94(3):140-9. doi: 10.1007/BF03044844.
2
PHLECO: a multicenter study of the fate of 1647 hospital patients treated conservatively without fibrinolysis and surgery.
Clin Investig. 1993 Jun;71(6):471-7. doi: 10.1007/BF00180062.
3
Use of thrombolytic drugs in non-coronary disorders.溶栓药物在非冠状动脉疾病中的应用。
Drugs. 1989 Nov;38(5):801-21. doi: 10.2165/00003495-198938050-00006.